Discontinued
Antibody (Suitable for clinical applications)
Application Notes
Specification | Recommendation |
---|---|
Recommended Dilution (Conc) | 1:50-1:100 |
Pretreatment | EDTABuffer pH 8.0 |
Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
CD105 Information for Pathologists
Summary:
Also called endoglin. CD105 is a regulatory component of the TGF-beta receptor complex. Mutations in CD105 cause Hereditary Hemorrhagic Telangiectasia type I (Am J Hum Genet 1997;61:68). It is required for hemangioblast and early hematopoietic development (Development 2007;134:3041)
Common Uses By Pathologists:
Specific and sensitive marker for tumor angiogenesis (better than CD31). Increased microvessel staining is also a prognostic factor for Acute lymphoblastic leukemia in children (Leuk Res 2007;31:1741)
Breast carcinoma (Am J Clin Pathol 2003;119:374, including node negative, Hum Pathol 2004;35:176) Chronic idiopathic myelofibrosis (Mod Pathol 2004;17:1513) Colorectal carcinoma (Mod Pathol 2004;17:197) Endometrial carcinoma (Gynecol Oncol 2006;103:1007) Esophageal adenocarcinoma (Hum Pathol 2006;37:861) Gastric carcinoma (Hum Pathol 2006;37:861) Hepatocellular carcinoma (BMC Cancer 2006;6:110) Meningioma (Acta Neuropathol 2007;114:147) Ovarian carcinoma (Int J Gynecol Cancer 2006;16:1789) Primary CNS lymphoma (J Neurooncol 2007;82:249) Prostate adenocarcinoma (Am J Clin Pathol 2007;127:572) and Squamous cell carcinoma of head and neck (Virchows Arch 2006;448:768), including tongue (Laryngoscope 2006;116:1175). Serum CD105 is associated with intrauterine growth restriction during pregnancy (J Clin Endocrinol Metab 2007;92:2831), preeclampsia (N Engl J Med 2006;355:992, Nat Med 2006;12:642), diabetic retinopathy (J Cell Mol Med 2005;9:692). Tissue CD105 is associated with progressive hepatic fibrosis in chronic HCV infection.
CD105 General Information | |
---|---|
Alternate Names | |
Molecular Weight | |
70.6 kDa | |
Chromosomal Location | |
q34.11 [chr: 9] [chr_start: 127815012] [chr_end: 127854756] [strand: -1] | |
Curated Database and Bioinformatic Data | |
Gene Symbol | ENG |
Entrez Gene ID | 2022 |
RefSeq Protein Accession(s) | NP_000109; NP_001265067; NP_001108225 |
RefSeq mRNA Accession(s) | NM_001114753; NM_001278138; NM_000118; |
RefSeq Genomic Accession(s) | NG_009551; NC_000009 |
UniProt ID(s) | P17813 |
PharmGKB ID(s) | PA27785 |
KEGG Gene ID(s) | hsa:2022 |
Associated Diseases (KEGG IDs) | Telangiectasia, hereditary hemorrhagic, 1 (HHT1) [MIM:187300]: A multisystemic vascular dysplasia leading to dilation of permanent blood vessels and arteriovenous malformations of skin, mucosa, and viscera. The disease is characterized by recurrent epistaxis and gastro-intestinal hemorrhage. Visceral involvement includes arteriovenous malformations of the lung, liver, and brain. {ECO:0000269|PubMed:10545596, ECO:0000269|PubMed:10625079, ECO:0000269|PubMed:10982033, ECO:0000269|PubMed:15024723, ECO:0000269|PubMed:15712270, ECO:0000269|PubMed:16525724, ECO:0000269|PubMed:16752392, ECO:0000269|PubMed:20414677, ECO:0000269|PubMed:7894484, ECO:0000269|PubMed:9157574, ECO:0000269|PubMed:9245986, ECO:0000269|PubMed:9554745}. The disease is caused by mutations affecting the gene represented in this entry. |
General Description of CD105 . | |
CD105 (endoglin) is a disulfide-linked homodimeric cell membrane glycoprotein. It was initially discovered in a human pre-B cell line. CD105 functions as a receptor for transforming growth factor (TGF) – beta1 and -beta3, and modulates TGF- beta signaling through interactions with TGF-beta receptors I and/or II. CD105 is a proliferation-associated and hypoxia-inducible protein abundantly expressed in angiogenic endothelial cells. Tumor microvessel density assessed by CD105 immunohistochemical staining in paraffin-embedded tissue sections correlates significantly with tumor aggressiveness and prognosis in many types solid tumors. |
There are no reviews yet.